product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
α-Synuclein Antibody
catalog :
2642
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, rat, baker's yeast
application :
western blot, immunohistochemistry, immunoprecipitation
citations: 11
Published Application/Species/Sample/DilutionReference
  • western blot; human; fig 1
  • western blot; mouse; fig 3
Duplan E, Giordano C, Checler F, Alves da Costa C. Direct α-synuclein promoter transactivation by the tumor suppressor p53. Mol Neurodegener. 2016;11:13 pubmed publisher
  • western blot; rat; fig 6
Wang J, Cao Y, Li Q, Yang Y, Jin M, Chen D, et al. A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation. Autophagy. 2015;11:2057-2073 pubmed publisher
  • immunohistochemistry; human; 1:1000; fig s5
Ziskin J, Greicius M, Zhu W, Okumu A, Adams C, Plowey E. Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia. Acta Neuropathol Commun. 2015;3:43 pubmed publisher
  • western blot; baker's yeast; fig 1
Wang S, Zhang S, Liou L, Ren Q, Zhang Z, Caldwell G, et al. Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease. Proc Natl Acad Sci U S A. 2014;111:E3976-85 pubmed publisher
Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda Suzukake M, et al. Propagation of pathological ?-synuclein in marmoset brain. Acta Neuropathol Commun. 2017;5:12 pubmed publisher
Brahmachari S, Ge P, Lee S, Kim D, Karuppagounder S, Kumar M, et al. Activation of tyrosine kinase c-Abl contributes to ?-synuclein-induced neurodegeneration. J Clin Invest. 2016;126:2970-88 pubmed publisher
Cai Z, Zhang X, Zhang Y, Li X, Xu J, Li X. The Impact of Paeoniflorin on α-Synuclein Degradation Pathway. Evid Based Complement Alternat Med. 2015;2015:182495 pubmed publisher
Cai Z, Xu J, Xue S, Liu Y, Zhang Y, Zhang X, et al. The E3 ubiquitin ligase seven in absentia homolog 1 may be a potential new therapeutic target for Parkinson's disease. Neural Regen Res. 2015;10:1286-91 pubmed publisher
Gispert S, Brehm N, Weil J, Seidel K, Rüb U, Kern B, et al. Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression. Hum Mol Genet. 2015;24:1061-76 pubmed publisher
Ho D, Yi S, Seo H, Son I, Seol W. Increased DJ-1 in urine exosome of Korean males with Parkinson's disease. Biomed Res Int. 2014;2014:704678 pubmed publisher
Lee Y, Wang S, Slone S, Yacoubian T, Witt S. Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease. PLoS ONE. 2011;6:e15946 pubmed publisher
product information
SKU :
2642S
Product-Name :
α-Synuclein Antibody
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Immunoprecipitation
Product-Category :
Neuroscience
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Polyclonal Antibody
MW :
18
Host :
Rabbit
Target :
Synuclein-alpha
Primary-Protein :
SNCA
Alt-Names :
Alpha-synuclein,MGC110988,NACP,Non-A beta component of AD amyloid,Non-A4 component of amyloid precursor,PARK1,PARK4,PD1,SNCA,SYUA,alpha-synuclein, isoform NACP140,non A-beta component of AD amyloid,non-A4 component of amyloid,synuclein, alpha (non A4 component of amyloid precursor)
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.